Global Large Molecule Injectable Drugs Market 2023-2027
The large molecule injectable drugs market is forecasted to grow by USD 191.45 bn during 2022-2027, accelerating at a CAGR of 7.86% during the forecast period. The report on the large molecule injectable drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing demand from emerging economies, increasing investments in pharmaceutical R and D, and advancements in gene and cell therapies.
Technavio's large molecule injectable drugs market is segmented as below:
By End-user
- Hospital pharmacies
- Retail pharmacies
- E-commerce
By Type
- Intravenous injection
- Muscle injection
- Subcutaneous injection
By Geographical Landscape
- North America
- Asia
- Europe
- Rest of World (ROW)
This study identifies the increased focus on precision medicine and personalized therapies as one of the prime reasons driving the large molecule injectable drugs market growth during the next few years. Also, increased partnership and collaboration among players and high spending by consumers on healthcare will lead to sizable demand in the market.
The report on the large molecule injectable drugs market covers the following areas:
- Large molecule injectable drugs market sizing
- Large molecule injectable drugs market forecast
- Large molecule injectable drugs market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading large molecule injectable drugs market vendors that include Boehringer Ingelheim International GmbH, Takeda Pharmaceutical Co. Ltd., AbbVie Inc., Amgen Inc., AstraZeneca Plc, Baxter International Inc., Biogen Inc., Bristol Myers Squibb Co., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Medtronic Plc, Merck and Co. Inc., Novartis AG, Novo Nordisk AS, Pfizer Inc., Sanofi, and Sun Pharmaceutical Industries Ltd.. Also, the large molecule injectable drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.